ClinicalTrials.gg

Program

AZD8359

A development code.

Its studies are mostly in Prostatic Neoplasms, led by AstraZeneca.

Furthest: phase 2, since Apr 8, 20261 company-led study, 1 open or runningNext primary completion: Nov 17, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 2since Apr 8, 2026Apr 8, 2026Nov 17, 2027phase 2 · NCT07529717

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 8, 2026First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT07529717 · 42 planned · United States, Australia, South Korea

Ahead

  1. Nov 17, 2027Primary completion: phase 2 study in Prostatic NeoplasmsNCT07529717

TargetBeta

STEAP2 →read by rule
“Phase I/II Dose Escalation & Dose Optimization Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD8359, a CD8-guided T Cell-engaging Antibody That Targets STEAP2, in Adult Participants With Prostate Cancer”study text, by rule · the study

Other programs on STEAP2

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07529717Prostatic Neoplasms · United States, Australia, South Korea2RecruitingNov 17, 202742

How it is read

Names in the registry

  • “AZD8359”, 4 entries

Codes read as this program: AZD8359.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.